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There are no approved therapeutics for the most
deadly nonsegmented negative-strand (NNS) RNA
viruses, including Ebola (EBOV). To identify chemical
scaffolds for the development of broad-spectrum
antivirals, we undertook a prototype-based lead
identification screen. Using the prototype NNS virus,
vesicular stomatitis virus (VSV), multiple inhibitory
compounds were identified. Three compounds
were investigated for broad-spectrum activity
and inhibited EBOV infection. The most potent,
CMLDBU3402, was selected for further study.
CMLDBU3402 did not show significant activity
against segmented negative-strand RNA viruses,
suggesting proscribed broad-spectrum activity.
Mechanistic analysis indicated that CMLDBU3402
blocked VSV viral RNA synthesis and inhibited
EBOVRNA transcription, demonstrating a consistent
mechanism of action against genetically distinct
viruses. The identification of this chemical backbone
as a broad-spectrum inhibitor of viral RNA synthesis
offers significant potential for the development of
new therapies for highly pathogenic viruses.
INTRODUCTION
The nonsegmented, negative sense (NNS) RNA viruses are an
order of viruses containingmany human diseases. These include
long-recognized pathogens, such as rabies, mumps, measles
and respiratory syncytial virus, as well asmore recently identified
pathogens, such as Nipah, Hendra, and Ebola viruses. For many
members of the NNS family, there are no approved therapeutics
or vaccines. Furthermore, rapid development of drug resistance
to monotherapy has been observed for other RNA viruses, such
as influenza (van der Vries et al., 2010; Zhu et al., 2012), suggest-
ing that multiple antivirals will be required for long-term effective
treatment of these diseases. Therefore, the development of new
therapies is warranted, especially ones that could target multiple
members of this human-pathogen laden virus order.424 Chemistry & Biology 20, 424–433, March 21, 2013 ª2013 ElsevieUnlike bacterial diseases, for which many broad-spectrum
antibiotics exist, there are no highly effective broad-spectrum
small molecules to treat viral diseases. To address this issue,
we have sought to identify small chemical probes that show
antiviral activity against multiple NNS virus family members.
Our hypothesis is that these molecules will target shared steps
in virus replication, identifying targets for broad-spectrum
antivirals. In this regard, one of the most promising potential
targets for therapeutic intervention is the viral RNA-dependent
RNA polymerase (RdRp).
The viral RdRp is the only protein with enzymatic activity that is
produced by all NNS family members. It is necessary for all
aspects of viral RNA synthesis, ranging from genome synthesis
to messenger RNA (mRNA) synthesis, capping, and polyade-
nylation (Whelan et al., 2004). The polymerase is a validated
antiviral target, as previous studies have shown compounds
that directly target the polymerase complex will inhibit virus
replication (Li et al., 2007). Additionally, compounds that target
cellular proteins important for viral RdRp stability also block viral
replication, indicating even indirect targeting of RdRp activity is
a valid approach for antagonizing RNA virus replication (Connor
et al., 2007).
To identify compounds that might act as broad-spectrum
probes of virus function, we used a two-stage screening
process. We initially set up a bifunctional screen to identify small
molecules that showed strong antiviral activity but little cell
toxicity. Our goal was to identify a small pool of lead compounds
that could then be tested in a second stage to identify com-
pounds that inhibited multiple NNS family members. Our initial
screening assay used the prototypical member of the NNS virus
family, vesicular stomatitis virus (VSV). VSV has significant
advantages as a virus for tissue culture-based screening, as it
is exceptionally well adapted to growth in culture, growing to
high titer and causing significant cytopathic effects in a short
period of time. Thus, any compounds that show antiviral activity
against this virus in cell culture will likely have the capacity to
dramatically blunt virus replication.
Once we developed a robust screen, we used the assay
to screen a library synthesized by the Center for Chemical
Methodology and Library Development at Boston University
(CMLD-BU) using diversity-oriented synthesis principles (Brown
et al., 2011; Tan, 2005). This library was a collection of over 2,000r Ltd All rights reserved
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Figure 1. Screen for Antiviral Compounds Using VSV Cytotoxicity
(A) This is a schematic of the screen.
(B) This is a representative sample plate from the screen. HeLa cells seeded in all wells and treated with library compounds in rows 2–11 and IFNa control in
row 12, columns E–H. Cells were infected with VSV moi 0.1 in rows 2–12 for 24 hr and then fixed and stained with crystal violet.
(C) This is the basic structure of the hit scaffold from the preliminary screen.
(D) These are the structures of the active, indoline alkaloid-type CMLD-BU compounds identified in the screen.
(E) HeLa cells were treated with dilution curve of CMLD-BU compounds for 1 hr before infection with wild-type VSV (WTVSV) and then fixed and stained as in the
screen.
(F) HeLa cells were treated with 50 mM CMLD-BU compounds for 1 hr before infection with WTVSV at moi 0.01. The virus was collected at specified time points
and titer determined by plaque assay. Error bars represent standard deviation.
See also Figure S1.
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chosen because it represented a wide range of chemical space
with a fairly limited number of compounds. This gave us the
opportunity to look for chemotypes that have not previously
been screened for activity against NNS viruses. Our interest in
this library was supported by the fact that previous screens using
similar composite libraries have identified compounds with
antimicrobial activities (Brown et al., 2011; Peng et al., 2007;
Thomas et al., 2008).
From our screen, several molecules targeting multiple viruses
were identified, underscoring the validity of this approach for
discovering broad-spectrum antivirals. From these, we focused
on one compound that inhibited the NNS viruses VSV and Ebola
(EBOV). Our analysis showed the compound limited viral mRNA
synthesis, suggesting that it was targeting the RdRp. We have
thus identified a probe that shows broad-spectrum inhibition of
negative-strand RNA virus infection at transcription, a step forChemistry & Biology 20, 4which few chemical probes exist. Further development of this
compound could lead to a therapeutic with broad-spectrum
activity against NNS RNA viruses.
RESULTS
Identification of Antiviral Compounds
To discover antiviral probes, we designed a high-throughput
screen to identify small molecules that showed antiviral activity
with little cellular toxicity. Our screen identified compounds
that inhibit infection of VSV, the prototype NNS virus. An example
of the overall assay design is shown in Figure 1A, with a sample
plate illustrated in Figure 1B. Row 1 contained only cells (with no
treatment or virus addition) and served as a negative control
for normal cell growth and staining. For rows 2–11, each well
was treated with an individual CMLD-BU compound at a final
concentration of approximately 25 mM. In row 12, four wells24–433, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 425
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activity) and fourwellswere left infected but untreated (as a nega-
tive control for VSV infection). One hour after the addition of
drugs or IFN, VSV was added to rows 2–12 at a multiplicity of
infection (moi) of 0.01 so that approximately 1% of the cells
would be initially infected. Productive virus infection would allow
spread and killing of all the cells in the well, while inhibition of
virus infection at any step in the virus lifecycle would prevent
cytopathic effects and cell death. At 24 hr postinfection (hpi),
cells were washed, fixed, and stained with crystal violet to deter-
mine the abundance of viable cells not affected by virus or drug.
In wells where VSV replication had taken place or where the
added compounds were cytotoxic, we expected little crystal
violet staining due to cell death induced by either phenomenon
(see Figure 1B, row 12, columns A–D). In wells not infected
with VSV (Figure 1B, row 1) or infected with VSV but treated
with IFN (Figure 1B, row 12, columns E–H), we expected a strong
purple crystal violet staining. In cells treated with compounds
that were not toxic and that blocked the replication of VSV, we
also expected strong purple staining, as seen in Figure 1B wells
F 5–7. These compounds were scored as positives. The screen
was carried out twice, and those compounds that inhibited VSV-
mediated cell death in both screens were considered hits and
were further investigated.
Our screening of the 2,000-compound CMLD-BU library iden-
tified a dozen high-confidence hit compounds at a 25 mM
concentration. Because the screen determined cellular viability
as ameasure of VSV infection, the hit compounds were not cyto-
toxic at the concentration screened; thus, wewere confident that
cellular death was not providing us with false positive hits.
Included in these hits were several synthetic indoline alkaloid-
type compounds that shared a common central chemical
scaffold. The scaffold of these active compounds (Figure 1C) is
named 1 for the purpose of this paper. In the library that we
screened, there were 16 additional N-14 amide analogs of 1
and 48 N-14 sulfonamides (see N-14 labeled in Figure 1C). The
larger number of the sulfonamides had been part of a separate
successful project (Brown et al., 2011) studying antimalarial
compounds. In our original screen, more than 100 analogs of 1
were screened. Of these, we identified six as hits (Figure 1D).
Interestingly, these hits were not evenly distributed among the
amide and sulfonamide compounds. All of the active com-
pounds came from the subset of members diversified at N-14
as amides. The sulfonamides invariably fell below the threshold
of activity deemed a hit, with the exception of one compound,
which was a very weak hit in the screen.
New lots of the hit compoundswere synthesized and tested as
serial dilutions in a bioassay similar to that shown in Figure 1A to
roughly determine the EC50 of each compound. One column in
each rowwas left untreated with drug or virus (far left). In succes-
sive columns, cells were incubated with decreasing dilutions of
drug, starting at 100 mM. One hour after drug treatment, cells
were infected with VSV at a moi of 0.01, and cell viability was as-
sessed at 24 hpi. The results of this test are shown in Figure 1E.
The five alkaloid-type compounds are in rows 1, 2, 4, 5, and 6.
Row 3 is a nonbasic, weakly antiviral compound. Row 7 shows
a serial dilution of IFN as a control for antiviral activity. The
complete inhibition of VSV infection by IFN is expected, as the
IFN-competent HeLa cells produce more IFN during the infec-426 Chemistry & Biology 20, 424–433, March 21, 2013 ª2013 Elsevietion. Row 8 shows a dilution of a control CMLD-BU compound
that was neither cytotoxic nor antiviral in the initial screen. Of
the five alkaloid compounds tested, all showed antiviral activity,
and the EC50 values ranged from 12.5 mM to 50 mM.
Confirmation of Antiviral Activity of Hits
We chose three of the five initial indoline alkaloid-type hits to
continue a more precise determination of the mechanism of
antiviral activity of these compounds. In our initial efforts, we
determined how well these compounds blocked the production
of new infectious virions following infection. HeLa cells were
treated with the compounds at 50 mM for 1 hr and then infected
with VSV atmoi 0.01. Viruswas collected at specified times post-
infection, and viral titers were determined by plaque assay. In the
absence of any CMLD-BU compound, VSV replication was
robust, reaching titers of 108 by 12 hpi (Figure 1F). However, in
cells infected with VSV but treated with CMLDBU3430, there
was a three-log decrease (99.9%) in viral replication, while in
the presence of CMLDBU3466 and CMLDBU3402, there was
four-log decrease. This highlighted the strong antiviral activity
of these compounds and suggested that CMLDBU3466 and
CMLDBU3402 showed the greatest efficacy.
Compounds with Activity against VSV Have Activity
against Other NNS Viruses
In earlier studies, we have noted that compounds with activity
against VSV have demonstrated inhibition of other, more patho-
genic negative-strand RNA viruses (Connor et al., 2007; Smith
et al., 2010). To examine whether the compounds identified in
this screen showed broad-spectrum antiviral activity, we tested
the efficacy against other negative-strand RNA viruses. We
tested Ebola virus, a member of the Filoviridae family, which is
a NNS virus like VSV, as well as Rift Valley fever virus, a member
of the Bunyaviridae family, which is a tripartite negative-
strand virus.
We tested the efficacy of several compounds against Zaire
Ebolavirus (EBOV) expressing enhanced GFP (EBOV-EGFP).
EBOV-EGFP was used to infect cells in a 96-well plate format,
and EGFP expression was read over time with several concen-
trations of compound. Figure 2A demonstrates that the com-
pounds inhibited EBOV infection when cells were treated with
40 mM CMLDBU3402, CMLDBU3279, or CMLDBU3466 and
infection levels read over time (data normalized to fluorescent
units of DMSO treatment control 5 days postinfection). To visu-
alize the inhibition, slides infected with EBOV-EGFP for 3 days
in the presence or absence of compound were fixed, stained
with DAPI to delineate nuclei, and imaged. Figure 2B shows
representative images in the absence (no drug) or presence of
40 mM CMLDBU3402 or CMLDBU3466. The compounds in-
hibited EBOV-EGFP infection, as fewer cells expressed EGFP
when treated with CMLD-BU compounds, and cells incubated
with either compound showed little cytotoxicity, as evidenced
by normal nuclear morphology.
To determine the EC50 for the compounds against EBOV, we
treated A549 cells with a dilution curve of the three compounds
from 100 mM to 5 mM and read the infection levels by EGFP
expression at 5 days postinfection. When normalized to infection
levels with DMSO alone, CMLDBU3402 and CMLDBU3466 have
similar curves, with an EC50 around 20 mM, while CMLDBU3279r Ltd All rights reserved
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Figure 3. Effect of CMLDBU3402 on Bunyavirus Gene Expression
A549 cells were treated with 20 mMCMLDBU3402 and infected with moi 0.1 or
moi 5.0 of RVFV-GFP for 49 hr.
(A) Cells infected with moi 5.0 were imaged in the absence (top panel) or
presence (bottom panel) of CMLDBU3402 at 49 hpi.
(B) Fluorescence of GFP expressed by RVFV was measured at 48 hpi, and
background values were subtracted. Error bars represent standard deviation.
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Figure 2. Effect of CMLDBU3402 on Ebola Virus Replication
(A) A549 cells were treated with 40 mMCMLDBU3402 and infected with EBOV-
EGFP at moi 1. Fluorescence was read at specified time points and data
normalized to relative fluorescence units (RFU) of DMSO. Error bars represent
standard deviation of triplicates.
(B) A549 cells were treated with 40 mMCMLDBU3402 and infected with EBOV-
EGFP at moi 1.0 for 65 hr. Cells were fixed and nuclei stained before imaging.
(C) A549 cells were treated with 5–100 mM CMLDBU3402 and infected with
EBOV-EGFP at moi 1. Fluorescence was read 5 days postinfection and data
normalized to DMSO. Error bars represent standard deviation of triplicates.
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pattern corresponded to the inhibition curves seen with VSV,
although the compounds were more potent against VSV (Fig-
ure 1D; data not shown).
Of the structurally similar compounds, CMLDBU3402 showed
the greatest inhibitory activity against both VSV and EBOV;
therefore, we chose to further investigate its antiviral activity.
We tested the efficacy of CMLDBU3402 against Rift Valley fever
virus (RVFV), a member of the Bunyaviridae family. Figure 3A
shows a micrograph of cells infected with EGFP-expressing
RVFV in the absence (top panel) or presence (bottom panel) of
CMLDBU3402. These micrographs suggest that there was little
effect of CMLDBU3402 on RVFV infection. This conclusion
was supported when high moi (5) and low moi (0.1) infections
with andwithout drug were quantified by fluorometry (Figure 3B).Chemistry & Biology 20, 4These data suggested that the compound does not universally
inhibit negative-strand RNA virus infection but does inhibit
NNS virus infection.
Reduction of Virus Growth by CMLDBU3402 Is
Independent of Stereochemistry
The structural similarities of the hit compounds suggest that they
inhibit virus replication through a similar mechanism. To begin to
determine the mechanism of action, we utilized the most potent
compound, CMLDBU3402. To ensure that the compound was
not cytotoxic at the concentrations used for treatment, we
determined CC50 values for CMLDBU3402. At 6 hr after drug
treatment, there was no cytotoxicity seen in HeLa cells up to
100 mM (data not shown). At 17 hr after drug treatment, there
was some cell death seen at drug concentrations over 80 mM;
however, this was not significant compared to DMSO-treated
cells (p value of 0.0762). These data correlate with the lack of
cytotoxicity seen in the original screen (Figure 1) and contend
that the concentrations used in this study are not cytotoxic.
Comparison of the structures of the antiviral compounds with
structurally similar compounds that lack antiviral activity indi-
cated that small changes in the side chains can have a large
effect on antiviral activity (data not shown). To determine
whether the absolute stereochemistry of CMLDBU3402 also
played an important role in its activity, CMLDBU3402 produced
from (L)-tryptophan and the enantiomer CMLDBU3402E,
prepared from (D)-tryptophan, were confirmed to be enantio-
merically pure by chiral high-performance liquid chromatog-
raphy (data not shown). Both compounds were tested for activity
against a VSV virus that expresses Renilla luciferase (VSV-rLuc).
A549 cells were treated with dilutions of CMLDBU3402 or
CMLDBU3402E for 45 min and then infected with VSV-rLuc at
a moi of 1, which allowed for expression of high levels of lucif-
erase in the absence of antiviral treatment. The infection was
allowed to progress for 24 hr before the cells were lysed with
Renilla-Glo reagent, read on a luminometer, and normalized to
DMSO treatment. Both CMLDBU3402 and CMLDBU3402E
inhibited infection to similar degrees (Figure 4A). These data
demonstrate that the chirality of the compound did not
dramatically alter its antiviral effect. Because the chirality of the24–433, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 427
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Figure 4. Effect of Drug Treatment on
Growth of VSV Protein Expression
(A) A549 cells were treated with CMLDBU3402 or
CMLDBU3402E and then infected with VSV-rLuc
at moi 1.0 for 16 hr and lysed and read on a
luminometer. Relative light units (RLU) were
normalized to DMSO control; error bars are stan-
dard deviation.
(B) HeLa cells were treated with 0, 10, or 25 mM
CMLDBU3402 for 1 hr before infection with
WTVSV at moi 10 for specified times. Cells were
lysed and immunoblotted for VSV M protein and
actin control.
(C) HeLa cells treated with 1, 10, or 25 mM
CMLDBU3402 or CMLDBU3402E were infected
with WTVSV at moi 10 for 6 hr. Cells were lysed
and immunoblotted for VSV G protein and actin
control.
(D) A549 cells were treated with 20 mM
CMLDBU3402 and then infected with VSV-EGFP
at moi 5 for 6 hr. Cells were fixed and stained for
VSV-G and nuclei.
(E) A549 cells infected with VSV-EGFP were
counted to determine percent infection in the
absence and presence of CMLDBU3402. Error
bars are standard deviation.
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pounds were used interchangeably.
CMLDBU3402 Inhibits Viral Gene Expression
The ability of CMLDBU3402 to block expression of virally en-
coded rLuc suggested the drug was blocking viral infection at
or before protein synthesis. To directly look at the effects of
native viral protein accumulation in the presence of drug, we
determined the level of the VSV matrix (M) protein in infected
cells in the presence or absence of CMLDBU3402. HeLa cells
were infected with VSV in the presence of 10 mM or 25 mM
CMLDBU3402. Cells were lysed at increasing times postinfec-
tion, and total protein was separated by SDS-PAGE and trans-
ferred to polyvinylidene fluoride (PVDF) for immunoblotting with
an anti-VSV M antibody. A representative result of these exper-
iments is shown in Figure 4B. In cells that were not treated with
drug, the expression of VSV M was readily detected, beginning
at 4 hr postinfection. The presence of either 10 mM or 25 mM
CMLDBU3402 decreased the expression of M protein at 4 hr
by greater than 90%. This same inhibition of M protein accumu-
lation was seen at 6 hr postinfection, with a dose-dependent
effect of drug concentration. To determine if expression of other
viral proteins was also inhibited, cells treated with either
CMLDBU3402 or CMLDBU3402E were lysed at 6 hpi, and the
recovered proteins were immunoblotted for the VSV glycopro-
tein (VSV-G). As shown in Figure 4C, both compounds were
highly effective at blocking expression of VSV-G at 25 mM.
To determine whether the decrease in viral protein expression
was a result of lower protein expression in all infected cells or
fewer cells being infected, immunofluorescence was performed
to examine the protein expression levels in individual cells. A549
cells were infectedwith a recombinant VSV that expresses EGFP
(VSV-EGFP) at a moi of 5. At 6 hpi, cells were fixed and stained
with an antibody against the VSV glycoprotein (red). Infection of
DMSO-treated cells with this virus resulted in the expression of428 Chemistry & Biology 20, 424–433, March 21, 2013 ª2013 Elseviehigh levels of EGFP and VSV-G (Figure 4D). In cells that were
treated with 20 mM CMLDBU3402, the expression of both
EGFP and the VSV glycoprotein were dramatically decreased.
Quantitation of several experiments showed that >60% of
DMSO-treated cells infected with VSV-EGFP expressed sig-
nificant levels of viral proteins, while fewer than 20% of
CMLDBU3402-treated cells infected with VSV-EGFP expressed
low levels of viral proteins (Figure 4F). These results suggested
that CMLDBU3402 decreased both the number of infected cells
and the protein expression in each cell and confirmed that
CMLDBU3402 acts to block virus infection at or before the level
of viral protein synthesis. We therefore began to test the possible
steps of the virus lifecycle, including virus entry, transcription,
and replication.
CMLDBU3402 Does Not Block Viral Entry
Recent studies have shown that some compounds targeting
VSV replication can inactivate the virus particle directly (Wolf
et al., 2010). To determine whether CMLDBU3402 was able to
act upon the assembled virus and inactivate it prior to infection,
virus and drug were coincubated for 1 hr at a concentration of
100 mM, which is over five times the EC50 value (Figure 1D).
Following the coincubation, the virus and drug mixture was
diluted past the point of drug efficacy, to 0.25 mM, and used to
infect untreated cells at moi 5 (lane 3). As controls, cells were
infected with virus alone (lane 1), infected with virus plus
0.25 mM CMLDBU3402, a concentration that does not show
antiviral activity (lane 5), or infected with virus plus 50 mM
CMLDBU3402, a concentration that effectively blocks infection
(lane 4). Cells were lysed and probed for expression of VSV-G
and VSV-M by immunoblot as above. Preincubation of the
drug directly with the virus did not inhibit virus infectivity (Fig-
ure 5A). Furthermore, pretreatment of VSV-rLuc virus with
CMLDBU3402 in a similar manner did not significantly inhibit
rLuc expression as read on a luminometer (p value 0.22;r Ltd All rights reserved
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Figure 5. Effect of Pretreatment of Virus with CMLDBU3402
(A) VSV and CMLDBU3402 were incubated for 1 hr before adding to cells at
a final concentration of 0.25 mM. As controls, 0.25 mM or 50 mM drug were
added to cells before infection with VSV. At 6 hpi, cells were lysed and
immunoblotted for VSV-G, VSV-M, or actin control.
(B) VSV-rLuc was incubated with CMLDBU3402 at 100 mM or anti-VSV-G
antibody 8G5 for 1 hr prior to adding to cells, for a final concentration of 1 mM
CMLDBU3402. As controls, cells were treated with 1 mM, 40 mM, or 8G5 prior
to infection with VSV-rLuc at moi 1.0. Sixteen hours postinfection, cells were
lysed and read on a luminometer. Error bars represent standard deviation of
triplicates.
(C) HeLa cells were treated with 25 mM CMLDBU3402 at specified times and
infected with WTVSV at moi 10. At 4 hpi, cells were lysed and immunoblotted
for VSV-G, VSV-M, and actin as a control.
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Figure 6. Effect of CMLDBU3402 on VSV Gene Expression
(A and B) BSR-T7 cells were infected with VACV-T7 and transfected with
plasmids expressing the VSV polymerase complex, N, P, and L, along with
a minigenome that expresses EGFP in the absence (A) or presence (B) of
CMLDBU3402.
(C and D) BSR-T7 cells were infected with VACV-T7 and transfected with
a plasmid that expresses GFP under the control of T7 in the absence (C) or
presence (D) of CMLDBU3402.
(E) [3H]uridine incorporation into viral mRNAs was measured on a scintillation
counter. Error bars represent standard deviation of triplicates.
(F) Cells infected with VSV at an moi 10 were pulsed with [3H]uridine to allow
incorporation into mRNA. Extracted RNA was run on a gel, and viral mRNA
bands for L, G/N, and P+M are labeled.
(G) Cells infected with VSV at an moi 10 and treated with DMSO,
CMLDBU3402E, or Ribavirin concurrent with infection or at 1 or 3 hr
postinfection. Cells were pulsed with [3H]uridine from 2–4 hr postinfection to
label viral mRNA. Extracted RNA was run on a gel, and viral mRNA bands for
G/N and P+M are labeled, with quantitation of P+M normalized to DMSO
presented.
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the virus particle. As a control, an anti-VSV-G inhibitory antibody,
8G5 (Lefrancois and Lyles, 1982a, 1982b), was incubated with
the virus or added during infection. In both cases, VSV infection
was inhibited, indicating that the time of preincubation is suffi-
cient for interaction and inhibition of VSV.
To determine whether CMLDBU3402 displayed a restricted
time of maximum activity, we carried out time-of-addition exper-
iments. Cells were infected with VSV, and drug was added to
cells either at the time of virus infection or at 1, 2, 3, or 4 hpi.
Accumulation of viral protein was determined at 6 hpi by immu-
noblotting cell lysates. The results, in Figure 5C, show that
concurrent treatment with drug maximally affected virus replica-
tion, but CMLDBU3402 was able to diminish the accumulation
of viral proteins when added after virus entry had occurred,
with a 50% reduction in viral protein production seen when
compound was added 2 hr postinfection. These data suggest
that CMLDBU3402 is able to inhibit the VSV lifecycle at a step
after initial entry and release of the virus into the cell but at or
before the expression of viral proteins.
CMLDBU3402 Inhibits anEarly Stage of Viral Replication
The finding that CMLDBU3402 is able to inhibit a step postentry
suggested the compound exerts its antiviral effect by in-
hibiting transcription or translation. To directly test the effectsChemistry & Biology 20, 4of CMLDBU3402 on viral transcription, a VSV minigenome
expression system was used. In this experiment, EGFP expres-
sion was directly dependent on the viral polymerase complex
without requiring earlier steps in the virus lifecycle. EGFP ex-
pression from the minigenome construct was measured in the
presence and absence of drug.
Cells were infected with Vaccinia virus expressing the T7
polymerase (VACV-T7) and transfected with a set of plasmids
that express the VSV polymerase complex proteins L, N, and P
and a VSV EGFP-containing minigenome RNA fragment. EGFP
would only be produced if the VSV polymerase transcribed
EGFP mRNA from the minigenome RNA template. Figure 6A24–433, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 429
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Figure 7. Effect of CMLDBU3402 on EBOVMinigenome-Based Gene
Expression
BSR-T7 cells were transfected with the Ebola virus polymerase complex
plasmids NP, VP35, L, and VP30 with a minigenome plasmid expressing rLuc
in the presence or absence of CMLDBU3402. Cells were then lysed and read
on a luminometer.
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CMLDBU3402 was added to the cells, EGFP expression was
greatly diminished (Figure 6B). Quantification of EGFP expres-
sion showed a decrease in EGFP signal to approximately 33%
of signal fromminigenome-transfected cells without drug added
(data not shown), suggesting that CMLDBU3402 was able to
directly inhibit VSV transcription.
To verify that CMLDBU3402 did not inhibit VACV-T7 expres-
sion or EGFP translation, cells infected with VACV-T7 were
transfected with a control plasmid that expressed EGFP in
a T7-dependent context. EGFP expression from a T7-driven
plasmid was not altered in the presence of CMLDBU3402
(Figures 6C and 6D). This indicated that the compound does
not directly inhibit VACV expression of T7, transcription by the
T7 polymerase, or translation of EGFP mRNA.
CMLDBU3402 Inhibits Viral Transcription
To determine more directly if CMLDBU3402 inhibits transcrip-
tion of viral RNA, baby hamster kidney (BHK) cells were infected
with VSV in the presence or absence of CMLDBU3402E
and pulsed with [3H]uridine from 4–6 hpi in the presence of
actinomycin-D to specifically label viral RNA synthesis. Without
drug, infected cells showed robust viral mRNA expression, as
demonstrated by the detection of four viral mRNA bands, corre-
sponding to L, G, N, and P+M, which are similar in size and
migrate together (Figure 6F). Addition of CMLDBU3402E
blocked the expression of viral mRNAs, indicating that the com-
pound blocks viral mRNA transcription. Figure 6E shows the
quantification of viral RNA synthesis from three experiments.
CMLDBU3402 inhibited viral protein expression when added
after infection (Figure 5C). To examine if the time of drug addition
impacts mRNA synthesis, CMLDBU3402E was added 1 hr
before VSV infection and 1 or 3 hr after VSV infection. Viral tran-
scription was labeled from 4–6 hpi with [3H]uridine in the pres-
ence of actinomycin D, as above. As seen in Figure 6G,
CMLDBU3402E inhibited viral mRNA accumulation most when
added prior to infection, to 54% of DMSO when the P+M band
was quantified; however, inhibition of viral mRNA synthesis
was seen when drug is added 1 hr after infection as well, to
74% of DMSO. As a control, ribavirin (which is also thought to
inhibit RNA synthesis) was added during virus infection, with
results similar to CMLDBU3402E. Both drugs inhibited VSV
infection most when added prior to infection, but they still inhibit
VSV mRNA synthesis when added 1 hr after infection.
CMLDBU3402 Inhibits Viral Transcription in Multiple
Viruses
The ability of CMLDBU3402 to specifically inhibit NNS viruses
suggests that the mechanism of action would be similar in
VSV- and EBOV-infected cells. To determine if the mechanism
of action against EBOV is similar to VSV, we used an ebolavirus
minigenome system in the presence of CMLDBU3402. An EBOV
minigenome plasmid carrying a Renilla luciferase reporter gene
was transfected into BHK cells expressing the T7 polymerase
along with support plasmids carrying EBOV NP, L, VP30, and
VP35 (Mu¨hlberger et al., 1999). The negative-sense copy of the
luciferase gene in the minigenome plasmid is made by T7 RNA
polymerase and subsequently encapsidated and transcribed
by the support EBOV RdRp complex. The resulting rLuc expres-430 Chemistry & Biology 20, 424–433, March 21, 2013 ª2013 Elseviesion was quantified using a luminometer. As shown in Figure 7A,
when the minigenome system was transfected into cells, rLuc
was expressed. Addition of 40 mM CMLDBU3402 blocked rLuc
expression, indicating that the mechanism of action against
EBOV is similar to that seen with VSV. Therefore, CMLDBU3402
blocks viral transcription of NNS viruses, including VSV and
EBOV.
DISCUSSION
Nonsegmented negative-strand RNA viruses include many
human diseases, but there are no approved therapeutics for
some of the most pathogenic, including Ebola virus. A broad-
spectrum antiviral could be used to treat infections with these
viruses and as-yet unidentified emerging NNS viruses in the
future. Here, we describe a simple screening approach that iden-
tified promising antiviral probes from a diverse small molecule
library. Together with other recently published efforts, this high-
lights that screening of the library can be fruitful in identifying
probe compounds with antimicrobial activities (Benson et al.,
2012; Brown et al., 2011; Thomas et al., 2008; Wei et al., 2009).
The identification of five indoline alkaloid-type hits in our
screen suggests that this structure (Figure 1C) may be particu-
larly well suited as an antiviral scaffold. In addition to our identi-
fication of compounds like CMLDBU3402, other screens have
found that related indoline alkaloid-type library members have
activity against hepatitis C (HCV) and malaria (Brown et al.,
2011; Wei et al., 2009). Of particular interest, related compounds
that were originally identified as inhibitors of HCV core assembly
with EC50 values in the high micromolar range were readily
improved through structural modifications to be effective inhibi-
tors at low nanomolar concentrations (Ni et al., 2011). This
suggests that the scaffold in this work, designated 1 in Figure 1C,
should be readily improvable through medicinal chemistry
derivatization following structure activity relationships.
Though the sublibrary of indoline-type compounds contained
only a limited number of samples (16 N-14 amides and 48 N-14
sulfonamides), preliminary structure-activity relationship trends
could be observed. First, N-14 amides were clearly more activer Ltd All rights reserved
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amides containing aryl groups were also more active than those
with only alkyl amides at N-14, though this latter suggestion
needs to be further explored. Finally, N-8 substituents were
examined, though only a very limited number of structural vari-
ants at this position (N-unsubstituted, methyl, allyl, benzyl, iso-
butenyl, and 2-butynyl) were in the small library initially screened.
Our experiments demonstrate that the lead compounds found
to have anti-VSV activity in our screen show antiviral activity
against EBOV as well and thus have the potential to be broad-
spectrum antiviral agents. These distantly related viruses both
have nonsegmented negative-strand RNA genomes, which
suggests that the inhibitors may be able to inhibit other NNS
viruses as well. While VSV and EBOV encode different genes
and have disparate strategies for entry, these viruses show
high sequence similarity in the RNA-dependent RNA polymerase
and are known to follow the same general mechanism for RNA
synthesis (Whelan et al., 2004). This suggested that the RdRp
is a potential target of the antiviral activity.
Examination of the mechanism of action of CMLDBU3402 is
consistent with this hypothesis. CMLDBU3402 does not interact
with the virion directly or inhibit virus entry in studies with VSV
(Figure 5). It does, however, block viral gene expression at an
early stage of infection and blocks reporter gene expression
from a minigenome system for both VSV (Figure 6) and EBOV
(Figure 7). Furthermore, VSV viral mRNA synthesis is inhibited
by CMLDBU3402 (Figure 6). This is the expected behavior
from a chemical probe that inhibits the viral polymerase. Thus,
we propose that CMLDBU3402 is inhibiting the RdRp of both
VSV and EBOV through a similar mechanism.
There are several possibilities for how CMLDBU3402 might
inhibit RNA polymerase activity. The compound is not an obvious
nucleoside analog (Figure 1D), which is encouraging in that this
decreases the likelihood that there will be nonspecific toxicity
effects to host transcription (Moyle, 2000). Studies have shown
that pyrimidine synthesis inhibitors can act as broad-spectrum
antiviral agents (Hoffmann et al., 2011), but CMLDBU3402
does not appear to be inhibiting pyrimidine or purine synthesis,
as supplementation with uridine or adenosine does not restore
viral infection (data not shown).
How CMDLBU3402 is acting to block viral RNA synthesis is
not yet clear. The compound could be interacting with the
RdRp complex directly to prevent activity and therefore inhibit
the virus. Direct interaction with viral proteins would be expected
to have minimal cytotoxicity but could lead to faster resistance
as the viral proteins evolve to avoid the inhibitor (Li et al.,
2007). To combat drug resistance, multiple therapeutics may
be used concurrently; therefore, the identification of inhibitors
at multiple steps in the virus lifecycle is ideal. CMLDBU3402
may also be interacting with host factors that are necessary for
viral transcription, therefore preventing virus infection. For
example, it has been previously shown that inhibition of HSP90
prevents replication of several NNS viruses (Connor et al.,
2007; Smith et al., 2010). It may be more difficult for a virus to
evade therapeutics targeting the host, making host-targeted
small molecules attractive drug candidates (Schwegmann and
Brombacher, 2008).
Although CMLDBU3402 has antiviral activity against disparate
viruses, it is important to note that it does not inhibit the replica-Chemistry & Biology 20, 4tion of all viruses. In our experiments CMLDBU3402 did not
inhibit the tripartite negative sense RNA Bunyavirus RVFV, which
suggests that the mechanism of action is restricted to the NNS
viruses. This may be due to intrinsic differences in the mecha-
nism of action of the polymerase for NNS viruses, or it may be
due to host factors that are necessary for NNS virus transcription
but not for other negative-strand virus or DNA virus transcription
(Whelan et al., 2004). Further understanding of the exact mech-
anism of action should elucidate the reason for the specificity of
this inhibitor.
There have been other broad-spectrum antivirals described in
the literature. Ribavirin, which has many proposed mechanisms
of action but is thought to target the virus polymerase, inhibits
a wide range of virus families, including Arenaviruses, Alphavi-
ruses, and Bunyaviruses (Crotty et al., 2000; Huggins, 1989;
Scheidel and Stollar, 1991; Streeter et al., 1973). The exact
mechanism of action of ribavirin has been difficult to determine,
and there are many negative side effects, including hemolytic
anemia and possible teratogenicity, limiting its use (Cameron
and Castro, 2001). Importantly, it has been shown that ribavirin
has very little effect on Ebola virus replication, suggesting that
CMLDBU3402 and ribavirin may attack viral polymerase activity
in different ways.
Recently, a pyrazine derivative compound, T-705, has been
shown to have broad-spectrum antiviral activity against Arenavi-
ruses, Bunyaviruses, and Orthomyxoviruses. It appears to act as
a nucleoside analog and inhibits the polymerase activity of influ-
enza (Furuta et al., 2009; Gowen et al., 2007; Takahashi et al.,
2003). CMLDBU3402 does not appear to act as a nucleoside
analog and does not inhibit Bunyavirus replication; therefore,
CMLDBU3402 appears to inhibit the polymerase complex in
a manner distinct from T-705.
The fact that several broad-spectrum inhibitors all appear to
alter polymerase function indicates how attractive this protein
complex is as a target for therapeutic development. Against
this group of broad-spectrum antivirals, CMLDBU3402 shows
a similar antiviral target, suggesting promise for future develop-
ment. Further work will be required to determine the precise
target of the compound and the extent of its broad-spectrum
capacity.
SIGNIFICANCE
There are few therapeutics available for many pathogenic
RNA viruses, including Ebola virus, a virus with mortality
rates up to 90% following infection, and a recently discov-
ered rhabdovirus associated with hemorrhagic fever. Identi-
fication of small molecules with broad-spectrum activity
against these types of viruses will be important tools in
developing successful therapies. Our study has identified
a set of indoline alkaloid-like compounds that inhibit the
replication of the prototype rhabdovirus VSV and the filovi-
rus EBOV. Analysis of the mechanism of action of one of
these compounds, CMLDBU3402, shows that the compound
is likely targeting the ability of the virus to synthesize RNA.
RNA synthesis is the main catalytic activity of RNA viruses,
so these compounds represent probes of a central virus
function and a potential drug target for the development of
effective broad-spectrum antivirals.24–433, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 431
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Cell Culture and Viruses
A549 (CCL-85), Vero-E6, and HeLa (CCL-2) cells were obtained from the
American Type Culture Collection (ATCC). Vero-E6 cells were used for growth
of Ebola virus. BHK21 cells (ATCC) were used for growth of VSV virus. VSV
virus stocks were made by infecting cells with wild-type San Juan at an moi
of 0.01. Supernatant fluids were harvested, clarified, and titrated on BHK21
cells.
Plaque Assays
BHK21 cells were infected with serial dilutions of clarified supernatant fluid
from infected cells, allowed to sit for one hour, and then covered with 1 3
Dulbecco’s modified Eagle’s medium (DMEM)-agar and incubated at 37
degrees for 24 hr. Cells were fixed with 4% formaldehyde for 1 hr. Then the
agar overlay was removed and cells stained with crystal violet.
Library Screening and Compounds
Generation of the screening library and chemical syntheses were performed by
the CMLD-BU, Boston, MA. HeLa cells were seeded at 4,000 cells per well in
96-well plates (Corning) the previous day and infected with VSV at an moi of
0.01 in the presence of compound. Final compound concentrations of the
initial screen were estimated to be approximately 25 mM based on an average
molecular weight for the library of 400. At 24 hpi, cells were washed in PBS,
fixed with methanol, stained with crystal violet, and washed. The wells were
scored based on color density. Interferon-awas obtained from PBL Interferon-
Source and used at a concentration of 1–10 IU as a positive control. For all
follow-up work, the compounds were resynthesized, validated, and used at
precise concentrations, as referenced in the text.
Compound Synthesis
Compounds were synthesized by the Center for Chemical Methodology and
Library Development at Boston University. See Supplemental Information
available online for details.
CC50 Assay
HeLa cells were seeded in 96-well plates the previous day and treated with
a dilution curve of CMLDBU3402 from 100 mM to 2.5 mM. After 6 or 17 hr,
the cells were lysed and luciferase read according to manufacturer’s instruc-
tions using CellTiter-Glo Luminescent Cell Viability Assay system (Promega)
on a LUMIstar Omega luminometer (BMG Labtech) for 1 s/well.
VSV Luciferase Assay
A549 cells were seeded in 96-well plates the previous day and infected with
VSV-rLuc at an moi specified in the text in DMEM without phenol. Cells were
lysed and luciferase read according to manufacturer’s instructions using
Renilla-Glo Luciferase Assay system (Promega) on a LUMIstar Omega lumin-
ometer (BMG Labtech) for 1 s/well. Unpaired t tests were run using GraphPad
Software to determine significance, as mentioned in the text.
Western Blots
BHK21 cells were infected at an moi specified in the text. At times indicated,
cells were lysed in radio-immunoprecipitation assay buffer with protease
and phosphatase inhibitors (1 mM phenylmethanesulfonylfluoride, 1 mM
benzamidine, 100 nM okadaic acid, 100 nM microcysin, and 100 nM sodium
fluoride). Twenty micrograms of total lysate were separated on a 10% SDS-
PAGE gel and transferred to PVDF (Bio-Rad 162-0177). Blots were probed
with polyclonal antibodies specific to viral M and G proteins and actin (Santa
Cruz, SC-47778).
Immunofluorescence
For VSV, A549 cells were seeded in six-well plates (Corning) the previous day
and infected with VSV-EGFP at moi 5 for 6 hr (Whitlow et al., 2006). Cells were
fixed with 4% formaldehyde and stained for VSV-G using 8G5 and DAPI to
delineate the nuclei. For EBOV, all pathogenic Ebola virus work was
completed in the BSL-4 laboratory at the United States Army Medical
Research Institute of Infectious Diseases (USAMRIID) following approved
standard operating procedures (SOP). A549 cells were seeded in chamber432 Chemistry & Biology 20, 424–433, March 21, 2013 ª2013 Elsevieslides the previous day and infected with EBOV-EGFP at moi 1.0 (Towner
et al., 2005). Cells were fixed at 65 hpi with 10% neutral-buffered formalin
for 24 hr. Cells were mounted with coverslips using ProLong Gold antifade
reagent with DAPI (Invitrogen) and imaged on an Axiovert 200M micro-
scope (Zeiss). For RVFV, all RVFV work was completed in the BSL-3+ labora-
tory at USAMRIID following approved SOPs. A549 cells were seeded in a
96-well plate (Corning) the previous day and infected with RVFV-GFP at
moi 0.1 or moi 5. Infection was monitored by GFP expression using a Nikon
Eclipse TE2000-S fluorescence microscope and imaged at 49 hpi. The
fluorescence was measured using a Modulus Fluorometer (Turner Bio-
systems) at 49 hpi.
VSV Minigenome Assay
BSR-T7/5 cells at approximately 90% confluence were infected with VACV-T7
at an moi of 1 in serum-free Opti-MEM (Life Technologies 31985-062). One
hour later, cells were transfected with wild-type VSV San Juan plasmids:
3 mg N, 1 mg P, 0.6 mg L, and 3 mg VSV()GFP using 10 ml Lipfectamine 2000
(Life Technologies 11668-019). Six hours after transfection, media was
removed and replaced with DMEM + 7% fetal bovine serum. At 24 hpi, resus-
pended cells were placed in a 96-well plate (Corning) and well fluorescence
was measured on a Tecan Infinity M1000 fluorescence plate reader (Tecan
Group) using 488 excitation and 507 emission wavelengths.
RNA Labeling
BHK21 cells at approximately 70% confluence were infected with VSV-
Indiana San Juan at an moi of 10. Cells were treated with 40 mM 3402E or
the equivalent volume of DMSO, as described in the text. At 3 hpi, 2 mg/ml
actinomycin-D was added to cells to inhibit cellular transcription. From
4–6 hpi, 20 mCi/ml [3H]uridine (Perkin Elmer NET367001MC)was added to cells
to label ongoing viral RNA synthesis. At 6 hpi, cells were lysed in Buffer RLT,
and total RNA was purified using the QIAGEN RNeasy mini kit (74106) accord-
ing to the manufacturer’s instructions. Purified RNA was separated on a 1%
denaturing agarose-formaldehyde gel. The gel was dehydrated and fixed
with methanol and incubated overnight in scintillation fluid to amplify the radio-
active signal. The gel was then dehydrated and exposed to film to detect
labeled RNA (Kodak BioMax MS).
Ebolavirus Minigenome Assay
BSR-T7/5 cells at approximately 90% confluence were transfected with the
Ebola virus plasmids (Mu¨hlberger et al., 1999) at the following ratios: Ebo-RLuc
1 mg: pTNP-Ebo 0.167 mg: pTVP35-Ebo 0.08 mg: pTL-Ebo 0.08 mg: pVP30-Ebo
0.1 mg using Lipofectamine 2000 (Life Technologies 11668-019). At 22 hr
posttransfection, cells were lysed and luciferase read according to the manu-
facturer’s instructions using Renilla-Glo Luciferase Assay system (Promega)
on a LUMIstar Omega luminometer (BMG Labtech) for 1 s/well.
Ebola Fluorescence Assay
All pathogenic Ebola virus experiments were completed in the BSL-4 labora-
tory at USAMRIID following approved SOPs. A549 cells were seeded in
96-well plates the previous day and infected with EBOV-EGFP at moi 1.0
with DMSO or 40 mMCMLDBU3402, CMLDBU3279, or CMLDBU3466. Plates
were read on SpectraMax M5 (Molecular Devices) using GFP settings: excita-
tion 485 nm, emission 515 nm, and 495 nm cutoff.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/
10.1016/j.chembiol.2013.02.011.
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